| Status | Awaiting development |
| Decision | None selected |
| Process | TA |
| ID number | 3855 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 November 2024 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Durvalumab with tremelimumab and chemotherapy within its marketing authorisation for treating unresectable or advanced urothelial cancer [ID3855]. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-March 2026. |
| 08 August 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late November 2025. |
For further information on our processes and methods, please see our CHTE processes and methods manual